Daniel Turner has become director of applications at Oxford Nanopore Technologies. He joins the company from the Wellcome Trust Sanger Institute, where he led the sequencing technology development group. Previously, he was a postdoc at the Sanger Institute. Turner holds a PhD in genetics from the University of Manchester Institute of Science and Technology and an undergraduate degree in biochemistry from the University of Oxford.
Illumina has added a number of people to its management team: Elizabeth Brady has become vice president of global supply chain, Emily Winn-Deen vice president of diagnostics development, and Melina Cimler vice president of quality and regulatory affairs.
In addition, Illumina has promoted Tristan Orpin to chief commercial officer, a new position. Previously, he was the company’s senior vice president of commercial operations, and before that, vice president of worldwide sales. Prior to joining Illumina, he held several positions at Sequenom, including vice president of sales and marketing and director of sales and marketing. Before that, he held several senior sales and marketing positions at Bio-Rad Laboratories. Orpin holds a BS in genetics and biochemistry from the University of Melbourne.
Terry Pizzie has become vice president for Europe at Pacific Biosciences. Prior to joining PacBio, he was director of global commercial operations at Genetix, now part of the Leica division of Danaher. Before that, he was senior vice president of commercial operations at Biacore, now part of GE Healthcare; and prior to that, vice president, Europe, at Applied Biosystems, now part of Life Technologies. He joined ABI in 1988 as a sales engineer and held various positions at the company, including vice president of sales and marketing for Europe. Pizzie holds a degree in physiology and biochemistry from the University of Reading in the UK.
Ajay Bansal joined Complete Genomics as chief financial officer in May, replacing John Curson, who is now the company’s vice president of financial operations. Previously, Bansal was executive vice president of corporate development and CFO at Lexicon Pharmaceuticals, and prior to that, CFO and executive vice president of corporate and business development for Tercica, now part of Ipsen. Before that, he was CFO of Nektar Therapeutics. Previously, he was director of operations analysis at Capital One Financial, and before that, a partner at financial advisory firm Mehta Partners. Prior to joining Mehta, he held product management and strategy roles at Novartis, and he was a management consultant with Arthur D. Little, McKinsey, and ZS Associates. Bansal holds an MS in operations research and an MBA from Northwestern University and a BS in mechanical engineering from the Indian Institute of Technology in Delhi.
Ken Prokuski came to Complete Genomics in January as vice president of operations, following several months as an independent consultant to the company. Prior to that, he was senior director of manufacturing operations at Applied Biosystems, now part of Life Technologies, and before that, material manager at Arico Coating Technology. Previously, he was director of materials at Toshiba America, and an operations manager at Millipore. Prokuski holds an MBA from Golden Gate University and a BA in psychology from Northeastern Illinois University.
Lewis Shuster joined Complete’s board of directors in April. He is the CEO of Shuster Capital, a company he founded that provides strategic and operating advice as well as angel funding to life sciences companies. Before that, he was CEO of Kemia, a drug discovery company. Prior to that, he held several operating executive positions at Invitrogen, now part of Life Technologies, and before that, he was chief financial officer of Pharmacopeia, and later chief operating officer of its Pharmacopeia Labs division. In 1992, he joined Human Genome Sciences as its first employee and executive vice president of operations and finance. Shuster holds an MBA from Stanford University and a BA in economics from Swarthmore College.
Stephen McLean has become a partner at Arsenal Capital Partners, a private equity firm. He is a founding partner of Merrill Lynch Capital Partners and its successor funds. McLean has been a founding investor and director of Agencourt Bioscience, now part of Beckman Coulter, and of Agencourt Personal Genomics, now part of Life Technologies. He was also an investor and member of the board of Packard Bioscience. He holds an MBA and a BS in economics from the Wharton School of the University of Pennsylvania.